Eridon

Quick links to important sections

Eridon

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eridon

Property Description
Active ingredient Domperidone
Form Tablet, oral solution, suspension, suppository
Pharmacological class D2 Dopamine Receptor Antagonist, Antiemetic, Prokinetic Agent
Common general use Relief of nausea and vomiting, and dyspeptic symptoms
Origin Synthetic compound

What is the Composition and Class of Eridon?

Eridon is a synthetic, single-ingredient medicine whose active ingredient is Domperidone, which is chemically a benzimidazole derivative. It is classified pharmacologically as a D2 dopamine receptor antagonist and is recognized functionally as both an antiemetic (for relieving sickness) and a prokinetic agent (for influencing gut movement). The core of the medicine is the Domperidone compound, which is combined with various pharmaceutical excipients appropriate for its final form.


What is Eridon's General Purpose?

The general purpose of Eridon is to provide relief for symptoms related to the sensation of sickness and discomfort arising from the upper digestive tract. As an antiemetic, it is intended to address the distressing symptoms of nausea and the accompanying reflex of vomiting. Furthermore, its function as a prokinetic agent connects it to the general relief of upper digestive issues, such as feelings of fullness or bloating, which are often associated with delayed gastric emptying or dyspeptic symptoms. Domperidone is used to help increase movement or contractions of the stomach and bowels. This helps ease discomfort by gently stimulating the natural movement of the digestive tract. The drug acts as a peripherally-acting dopamine antagonist, indicating its action is largely focused outside the main central nervous system.


What Forms of Eridon are Available?

Eridon is available in multiple dosage forms to accommodate various patient needs and preferred routes of administration. These preparations include solid tablets for easy swallowing, as well as liquid preparations such as oral suspension or oral solution. Additionally, the medicine can be formulated as suppositories, providing an alternative delivery method via the rectal route, which is particularly useful when oral intake is compromised due to persistent vomiting.

Regulatory References

  1. Gastroparesis: MedlinePlus Medical Encyclopedia

What side effects are possible with Eridon?

Possible Side Effects and Safety Information

The safety profile for Eridon (Domperidone) is categorized by regulatory bodies based on the frequency and the physiological system affected. Adverse reactions are grouped across several System-Organ Classes, including Gastrointestinal, Nervous System, Endocrine, and Cardiac Disorders.


Frequency-Classified Reactions

The most frequently reported adverse event is dry mouth, which is generally classified as Common in official product labeling. Uncommon reactions may include effects such as headache, anxiety, somnolence (drowsiness), diarrhoea, and rash.


Serious Adverse Reactions and Safety Constraints

The most serious safety concerns documented in regulatory information relate to the Cardiac System. These serious adverse reactions include the risk of QTc prolongation, ventricular arrhythmias, and sudden cardiac death. Extrapyramidal disorders and severe anaphylactic reactions are also officially noted as very rare but serious risks.

Safety documents specify that the risk of serious cardiac side effects may be higher in the first few days of treatment and may also be associated with longer-term exposure. Therefore, its use is subject to significant restrictions.


Population and Condition Restrictions

Eridon is contraindicated by regulators in several specific patient conditions. These include patients with moderate to severe hepatic impairment, individuals with a known prolongation of cardiac conduction intervals (e.g., QTc), and those with underlying cardiac diseases (like congestive heart failure) or significant electrolyte disturbances. Older adults are identified as a population potentially at increased risk of serious cardiac events.

This framework ensures that the absolute safety constraints and potential serious risks, particularly cardiac concerns, are clearly defined within the official regulatory scope.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

An overdose of Eridon (Domperidone) is associated with serious physiological risks, primarily affecting the nervous and cardiovascular systems, and requires immediate emergency medical intervention.


Documented Overdose Manifestations

Official regulatory labeling states that overdose may lead to Central Nervous System (CNS) effects, including somnolence, disorientation, and agitation. More severe presentations include convulsions and changes in consciousness. A specific risk noted for infants and children is an increased susceptibility to extrapyramidal reactions (involuntary movements).

Severe Outcomes and Emergency Actions

The most critical documented risks are cardiac disorders. Overdose or high-dose exposure is associated with prolongation of the QTc interval, which can lead to life-threatening arrhythmias such as ventricular fibrillation and cardiac arrest. Due to these severe outcomes, regulatory documents strictly mandate that individuals seek immediate medical attention and contact emergency services.

Management and Monitoring

No specific antidote is known for Domperidone overdose. Management consists of symptomatic and supportive measures. Official procedural requirements include mandatory ECG monitoring to check for arrhythmias, and close medical supervision, often requiring hospital observation for up to 24 hours. Procedures like the use of activated charcoal may be considered to reduce absorption.

Therapeutic Uses of Eridon

Main uses of Eridon

Eridon contains the active ingredient risperidone, which belongs to a class of medications known as antipsychotics. It is primarily used to manage symptoms associated with certain mental health and behavioral conditions by helping to restore the balance of specific natural substances in the brain.

Schizophrenia

Eridon is used for the treatment of schizophrenia, a condition characterized by symptoms such as hearing, seeing, or feeling things that are not there, mistaken beliefs, unusual suspiciousness, or becoming withdrawn. The medication helps to alleviate these symptoms and may also be used to maintain clinical improvement in long-term therapy.

Manic Episodes in Bipolar Disorder

This medication is used to treat moderate to severe manic episodes associated with bipolar disorder. These episodes are typically characterized by a period of particularly elevated, expansive, or irritable mood, along with inflated self-esteem, decreased need for sleep, racing thoughts, and rapid speech.

Persistent Aggression in Conduct Disorder

Eridon is indicated for the short-term symptomatic treatment of persistent aggression in children and adolescents with subaverage intellectual functioning or mental retardation. It is used when aggressive or other disruptive behaviors require pharmacological intervention as part of a comprehensive treatment program.

Aggression in Dementia

In specific cases, Eridon is used for the short-term treatment of persistent aggression in patients with moderate to severe Alzheimer’s dementia who do not respond to non-pharmacological approaches and when there is a risk of harm to themselves or others.

Benefits and Expected Outcomes

The primary goal of treatment with Eridon is the stabilization of mood and the reduction of psychotic symptoms. Patients may experience several benefits during the course of treatment:

  • Reduction in hallucinations and delusions: Helping to clear the mind and improve the ability to distinguish between what is real and what is not.
  • Improved social functioning: By managing behavioral symptoms, individuals may find it easier to interact with others and participate in daily activities.
  • Mood stabilization: Reducing the intensity of manic episodes, leading to more consistent emotional states.
  • Management of behavioral disturbances: Decreasing the frequency and severity of aggressive or disruptive outbursts in specific patient populations.

Regulatory References

  1. MHRA drug safety update

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Eridon — Official Regulatory Information

Official regulatory documents strictly define populations who can and cannot use Eridon (domperidone) based on the presence of specific health conditions or life stages.

Classification Populations that Must Not Use (Contraindicated)
Cardiovascular Status Patients with existing cardiac conduction issues (especially prolonged QTc), significant electrolyte disturbances (e.g., hypokalaemia, hypomagnesaemia), or underlying cardiac disease (e.g., congestive heart failure).
Concomitant Medication Patients taking potent CYP3A4 inhibitors (e.g., certain antifungals or antibiotics) or other QT-prolonging medicines.
Organ Function Patients with moderate or severe hepatic impairment (liver failure).
Gastrointestinal Integrity Conditions where gastrointestinal motility stimulation is dangerous (e.g., hemorrhage, mechanical obstruction, or perforation).
Other Conditions Known hypersensitivity to Eridon or any excipients; prolactin-releasing pituitary tumor (prolactinoma).

Populations for whom use is restricted or requires caution include adults over 60 years of age and patients with renal impairment. Official labeling typically does not establish use for pediatric patients (under 12 years or under 35 kg). Use during pregnancy and lactation is generally not recommended unless the expected benefit is determined to outweigh the potential risk.

What should I know about interactions with other medicines?

Eridon (risperidone) interacts with other products primarily through its effects on the central nervous system (CNS) and its hepatic metabolism. The concurrent use of alcohol and other centrally-acting drugs may lead to enhanced sedation and CNS depression. Eridon may also increase the effects of drugs with hypotensive potential and may antagonize the therapeutic effects of levodopa and other dopamine agonists.

Eridon is metabolized mainly by the enzyme CYP2D6 and, to a lesser extent, by CYP3A4. Concomitant use with strong CYP2D6 enzyme inhibitors like fluoxetine or paroxetine can significantly increase Eridon plasma concentrations, necessitating a dose reduction of Eridon, typically not to exceed 8 mg per day. Conversely, strong CYP3A4 enzyme inducers such as carbamazepine may substantially decrease Eridon plasma levels, potentially requiring an increase in the Eridon dose, up to double the usual amount. Cimetidine and ranitidine also increase Eridon’s bioavailability. Additionally, caution is advised with QT-prolonging agents due to a theoretical risk of additive effects.

A specific warning exists for elderly patients with dementia-related psychosis receiving Eridon and the diuretic furosemide, as this combination has been associated with a higher incidence of mortality compared to Eridon alone.

Mechanism of Action

How Eridon works

Eridon functions primarily as a dopamine receptor antagonist. Its molecular target is the D2 dopamine receptor located in peripheral tissues, specifically within the Chemoreceptor Trigger Zone (CTZ) and the walls of the upper gastrointestinal tract.

The mechanism involves the blockade of these peripheral D2 receptors. In the CTZ, this interaction modifies signaling pathways that influence the emetic reflex. In the gastrointestinal tract, the inhibition of D2 receptors enhances cholinergic input, a mechanistic cascade that modulates gut motility.

This modification leads to several systemic physiological consequences: an increase in esophageal peristalsis, a measurable rise in lower esophageal sphincter pressure, and enhanced antral and duodenal peristalsis. The overall effect on the digestive system is the normalization of the speed of transit through the upper tract and the facilitation of gastric content emptying.

Dosage and Administration Information

Official Administration Guidelines for Eridon

Eridon (Domperidone) is used according to specific instructions that define the maximum dosage, frequency, and duration of treatment.

Instruction Detail
Route of Administration Oral (tablets, solution) and Rectal (suppositories). Tablets must be swallowed whole with liquid.
Timing with Meals Oral preparations should be taken before meals (15 to 30 minutes prior), as food intake can delay the drug’s absorption.
Standard Dosing The maximum oral dose for adults and adolescents (ge 35 kg) is 10 mg per administration, taken up to three times daily. The total daily dose must not exceed 30 mg.
Duration and Frequency The maximum treatment duration is usually limited to one week (7 days), using the lowest effective dose for the shortest time required. An interval of at least 8 hours should be left between doses.
Population-Specific Rules For patients with severe renal impairment, the dosing frequency must be reduced (to once or twice daily) on repeated administration, due to the drug’s prolonged half-life in this population. The medicine is generally unsuitable for pediatric patients weighing less than 35 kg.
Missed Dose Rule If a scheduled dose is missed, it should be omitted, and the patient should resume the usual dosing schedule without attempting to double the dose.

These official instructions establish Eridon as a low-dose, short-term treatment. The structure mandates strict adherence to the 30 mg daily maximum and the maximum seven-day duration, limiting its use to acute, short-lived symptomatic management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eridon


Evidence for Relief of Nausea and Vomiting (Approved Use)

Research on Eridon was studied for conditions characterized by fluctuating or episodic manifestations such as sickness and vomiting, relying primarily on short-term, randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity. The main research examined outcomes related to episodic or acute changes, specifically monitoring the frequency and intensity of vomiting episodes and patient-reported outcomes describing perceived discomfort from nausea.

Studies monitored responses over defined time intervals, generally focusing on symptomatic patterns over not exceeding one week. Official evaluations contribute to understanding symptom patterns and the regulatory decision-making related to its current use in managing acute symptoms. Follow-up durations were limited in the primary efficacy trials, meaning long-term effects are not fully established.


Research on Dyspeptic Symptoms and Digestive Motility

Historically, Eridon was studied for outcomes related to physical discomfort in the upper digestive tract, such as feelings of fullness or slow digestion (dyspepsia). The research examined studies exploring outcomes related to gastrointestinal movement. Study designs included various RCTs that often explored intermediate time frames, sometimes ranging up to six weeks.

Findings indicate that studies reported how symptoms evolved in the observed populations. However, official sources indicate that the evidence is limited and heterogeneous when assessing the structure of the evidence for long-term use. The certainty remains low regarding the long-term consistency of these findings, leading to restrictions on this use in many regulatory settings.


Evidence in Specific Age Groups and Patient Populations

Eridon was evaluated in studies involving adults and adolescents (age 12 and older). Research examined the use of Eridon in children younger than 12 years; however, findings were mixed. Regulators have concluded that data for certain groups remain insufficient to support the authorized use for that population, and results apply only to the populations studied (older adolescents and adults).

Frequently Asked Questions (FAQ)

Common questions about Eridon (FAQ)


Q: How quickly should I expect to feel a difference after starting Eridon?

A: According to official regulatory labeling, the active ingredient in Eridon is rapidly absorbed after you take it. The drug typically reaches its peak concentration in the bloodstream approximately one hour after an oral dose. This rapid absorption pattern indicates the medication begins acting relatively quickly.


Q: What are the most common mild side effects reported for Eridon?

A: Regulatory documents categorize adverse events by frequency. The most frequently reported mild side effect is dry mouth. Other uncommon reactions that have been reported include headache, anxiety, somnolence (drowsiness), diarrhea, and a rash.


Q: Do Eridon side effects get better or worse over time?

A: Official warnings primarily focus on the serious cardiac risks, stating that this risk may be higher in the first few days of starting treatment. Regulatory labels do not generally provide information on how common, mild side effects may progress or change over the short, authorized duration of use.


Q: Does Eridon interact negatively with alcohol?

A: Official product information advises caution regarding the combination of Eridon and alcohol. The concurrent use of alcohol may lead to enhanced sedation and central nervous system (CNS) depression. Due to the potential for enhanced effects, consulting a healthcare provider about alcohol consumption is recommended.


Q: What are the signs of a serious, but rare, side effect of Eridon?

A: The most serious concerns documented in official sources relate to the heart and nervous system. Signs of a serious heart rhythm issue may include experiencing palpitations, trouble breathing, or loss of consciousness. Uncontrolled movements are a sign of extrapyramidal disorders, and swelling of the hands, face, or throat can indicate a severe allergic reaction.


Q: How common are weight changes (gain or loss) reported with Eridon?

A: Official frequency lists for Eridon do not typically include weight changes in the common or uncommon categories. Although effects on the endocrine system are noted, weight fluctuations are not emphasized as a frequent or uncommon side effect in the primary regulatory documentation.


Q: What happens when you stop taking Eridon?

A: While the authorized use of Eridon is short-term, sudden discontinuation has been noted in post-marketing surveillance reports. There have been reports of neuropsychiatric adverse events (such as anxiety, depression, or difficulty sleeping) when the drug is stopped, particularly if it was used at higher-than-recommended doses.


Q: Do I need to taper off Eridon, or can I stop suddenly?

A: Eridon is typically prescribed for a maximum duration of seven days, using the lowest effective dose. This short treatment limit suggests sudden cessation is the intended method for on-label use. Any changes to how you stop taking the drug should be discussed with a doctor.


Q: How is Eridon stored, and does it expire quickly?

A: The medicine should be kept at a controlled room temperature (between 20 C and 25 C) and protected from light and moisture. The medication should be kept in the original, tightly closed container and out of the sight and reach of children. The specific shelf life (expiration date) is typically found printed on the packaging.


Q: Can Eridon cause fatigue or drowsiness during the day?

A: Somnolence (drowsiness) is listed as an uncommon side effect in official product information. If a person experiences drowsiness or other central nervous system (CNS) related effects, the drug could affect their daily function.


Q: Does Eridon change the way other medications are absorbed?

A: Eridon is not explicitly noted to change the absorption of most other medications. However, regulatory information states that when gastric acidity is reduced (which can be caused by some other drugs), Eridon's own absorption may be impaired. This highlights the importance of proper timing.


Q: Can Eridon be cut in half if the pill is scored?

A: Official administration guidelines state that Eridon oral tablets must be swallowed whole with liquid. Unless the drug monograph specifically authorizes splitting or crushing, it is generally not advised to cut the tablet, as this may alter its intended release or absorption.


Q: What should I do if I forget to take a dose of Eridon?

A: The official missed dose rule is to omit the missed dose entirely. You should then resume your usual dosing schedule at the next scheduled time without attempting to take a double dose to make up for the one you missed.


Q: Does Eridon have to be taken with food, or can it be taken on an empty stomach?

A: Oral preparations of Eridon should be taken before meals (typically 15 to 30 minutes prior). This timing is recommended because food intake can delay the drug's absorption, potentially making it less effective when you need it.


Q: What is the average duration of treatment with Eridon?

A: While the average duration is not strictly defined, regulatory guidelines place a firm limit on its use. The maximum treatment duration is usually limited to one week (7 days), as it is intended for acute, short-lived symptomatic management.


Q: Can Eridon affect my ability to drive or operate machinery?

A: At standard doses, Eridon is generally not expected to affect the ability to drive or use machines. However, if a person experiences side effects such as drowsiness (somnolence), confusion, or impaired awareness, it is recommended that a person refrain from driving or operating machinery.


Q: Is Eridon known to cause or worsen anxiety?

A: Anxiety is listed as an uncommon side effect in the official product labeling. In addition, some regulatory reports note that anxiety can be a symptom experienced by specific patients upon discontinuing the medication.


Q: Is there a generic version of Eridon available?

A: Yes. Eridon contains the active ingredient Domperidone, which is an established pharmaceutical compound. Consequently, generic versions of the medicine are widely available in the countries where the drug is authorized for sale.


Q: Does Eridon help with symptoms or does it treat the underlying condition?

A: Eridon is indicated for the relief of symptoms such as nausea, vomiting, and dyspeptic symptoms. It functions to manage these discomforting manifestations by stimulating gut movement and is not considered a cure that treats the underlying cause of the condition.


Q: Can Eridon cause dizziness or lightheadedness when standing up?

A: Regulatory documents warn that Eridon may increase the effects of medications that have hypotensive potential (lowering blood pressure), which can cause symptoms like dizziness or lightheadedness. Dizziness is also a recognized sign of potential serious cardiac events.


Q: Is Eridon a controlled substance?

A: In most major jurisdictions, including the United States, Eridon (Domperidone) is not a scheduled or controlled substance under the Controlled Substances Act or equivalent national frameworks.


Q: How does Eridon affect my energy levels?

A: The official product labeling lists somnolence (drowsiness) as an uncommon side effect. If a person experiences this side effect, it could be interpreted as a reduction in their typical energy levels.


Q: What is the purpose of the different strengths/dosages Eridon is available in?

A: Eridon is available in multiple forms (e.g., tablets, solution, suppositories) and strengths. These different doses are intended to allow for treatment using the lowest effective dose for the shortest time, with dose adjustments considered for factors like weight (for adolescents ge 35 kg) or symptom severity.


Q: Are there specific patient groups where Eridon is generally avoided?

A: Yes. The drug is contraindicated (must not be used) in patients with severe liver impairment, existing heart rhythm issues, or those taking specific interacting medications. Caution is also required or recommended for older adults and patients with reduced kidney function.


Q: What is the longest period a person has safely taken Eridon?

A: Regulatory authorization limits the maximum treatment duration to typically one week (7 days) for its on-label use. While long-term safety data are limited, the use of the drug for extended periods is not authorized due to potential risks, particularly those concerning the heart.


Q: Is a headache a common side effect when starting Eridon?

A: Headache is listed as an uncommon side effect in the official product information. This means it is not one of the most frequently reported adverse events. The risk is associated with the use of the medicine, not specifically the moment treatment is initiated.

How should Eridon be stored and disposed of?

Eridon must be stored according to regulatory specifications to ensure stability and safety.

Required Storage Conditions

Detail Requirement
Temperature Range Controlled room temperature: 20 C to 25 C (68 F to 77 F). Do not freeze.
Environmental Protection Protect from light and moisture.
Packaging Keep in the original container and ensure the container is tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Eridon must be disposed of according to local regulations. The preferred method is to use a drug take-back program or authorized collection site. If a take-back option is unavailable, the medicine may be mixed with an unappealing substance (like dirt or coffee grounds), placed in a sealed container, and then discarded in the household trash. It must not be flushed down the toilet or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eridon found in:

A-Z Index: